Nemonapride

Nemonapride
Clinical data
Trade names	Emilace (JP, CN)
Other names	Emonapride; Emirace; YM 09151-2; YM09151-2; YM 09151; YM09151
AHFS/Drugs.com	International Drug Names
Routes of; administration	Oral
Drug class	Dopamine D2, D3, and D4 receptor antagonist; Serotonin 5-HT1A receptor partial agonist; Antipsychotic
ATC code	None;
Legal status
Legal status	Rx-only (JP);
Pharmacokinetic data
Metabolism	Primarily CYP3A4
Elimination half-life	2.3–4.5 hours
Identifiers
	IUPAC name N-(1-benzyl-2-methylpyrrolidin-3-yl)-5-chloro-2-methoxy-4-(methylamino)benzamide;
CAS Number	75272-39-8;
PubChem CID	4452;
IUPHAR/BPS	983;
DrugBank	DB19314;
ChemSpider	4297;
UNII	Q88T5P3444;
KEGG	D01468 ;
ChEBI	CHEBI:64217;
ChEMBL	ChEMBL20734;
PDB ligand	AQD (PDBe, RCSB PDB);
CompTox Dashboard (EPA)	DTXSID0042612 ;
Chemical and physical data
Formula	C21H26ClN3O2
Molar mass	387.91 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1C(CCN1CC2=CC=CC=C2)NC(=O)C3=CC(=C(C=C3OC)NC)Cl;
	InChI InChI=1S/C21H26ClN3O2/c1-14-18(9-10-25(14)13-15-7-5-4-6-8-15)24-21(26)16-11-17(22)19(23-2)12-20(16)27-3/h4-8,11-12,14,18,23H,9-10,13H2,1-3H3,(H,24,26); Key:KRVOJOCLBAAKSJ-UHFFFAOYSA-N;
	(verify)

Nemonapride, also previously known as emonapride and sold under the brand name Emilace, is an atypical antipsychotic which is used in the treatment of schizophrenia. It is taken by mouth.

Side effects of nemonapride include akathisia, dystonia, hypokinesia, tremor, hypersalivation, and hyperprolactinemia, among others. The drug acts as a dopamine D₂, D₃, and D₄ receptor antagonist. To a lesser extent, it is also a serotonin 5-HT_1A receptor partial agonist. Structurally, nemonapride is a benzamide derivative and is related to sulpiride and other benzamides.

Nemonapride was introduced for medical use in either 1991 or 1997. It was developed and marketed by Yamanouchi Pharmaceuticals. The drug is approved only in Japan and China.